JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 8, 2007; DOI: 10.1124/jpet.106.117721


0022-3565/07/3212-616-625$20.00
JPET 321:616-625, 2007
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.106.117721v1
321/2/616    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deeb, D.
Right arrow Articles by Gautam, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deeb, D.
Right arrow Articles by Gautam, S. C.

CELLULAR AND MOLECULAR

Curcumin [1,7-Bis(4-hydroxy-3-methoxyphenyl)-1–6-heptadine-3,5-dione; C21H20O6] Sensitizes Human Prostate Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand/Apo2L-Induced Apoptosis by Suppressing Nuclear Factor-{kappa}B via Inhibition of the Prosurvival Akt Signaling PathwayFormula

Dorrah Deeb, Hao Jiang, Xiaohua Gao, Shaza Al-Holou, Andrew L. Danyluk, Scott A. Dulchavsky, and Subhash C. Gautam

Department of Surgery (D.D., X.G., S.A-H., A.L.D., S.A.D., S.C.G.) and Department of Neurology (H.J.), Henry Ford Health System, Detroit, Michigan

Our previous studies have shown that dietary pigment curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1–6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L)-induced apoptosis by inhibiting nuclear factor (NF)-{kappa}B. In the present study, we demonstrate that activated (phosphorylated) Akt kinase plays a pivotal role in regulation of NF-{kappa}B and sensitization of LNCaP and PC3 prostate cancer cells to TRAIL by curcumin. Curcumin inhibited the expression of phospho-Akt (p-Akt), which was not due to activation of phosphatase and tensin homolog deleted on chromosome 10 phosphatase activity by curcumin. Because NF-{kappa}B is a downstream target of Akt, we investigated whether inhibition of NF-{kappa}B by curcumin is mediated through suppression of p-Akt. Data demonstrate that treatment of PC3 cells with SH-6 (JAm Chem Soc 125:1144–1145, 2003), a specific inhibitor of Akt, or transfection with small inhibitory RNA (siRNA)-Akt not only inhibited p-Akt but also abrogated the expression and transcriptional activity of NF-{kappa}B. Furthermore, overexpression of constitutively active Akt1 in cancer cells prevented the inhibition of NF-{kappa}B by curcumin. In addition, treatment with SH-6 or transfection with siRNA-Akt sensitized PC3 cells to TRAIL-induced cytotoxicity. On the other hand, SH-6 does not inhibit NF-{kappa}B or sensitize DU145 cancer cells to TRAIL because these cells do not express p-Akt. Because expression of antiapoptotic Bcl-2, Bcl-xL, and X-chromosome-linked inhibitor of apoptosis protein (XIAP) is regulated by NF-{kappa}B, both curcumin and SH-6 decreased the levels of these proteins in PC3 cells through inhibition of NF-{kappa}B. Furthermore, gene silencing of Bcl-2 with siRNA-Bcl-2 sensitized PC3 cells to TRAIL. Collectively, these data define a pathway whereby curcumin sensitizes prostate cancer cells to TRAIL by inhibiting Akt-regulated NF-{kappa}B and NF-{kappa}B-dependent antiapoptotic Bcl-2, Bcl-xL, and XIAP.


Received November 28, 2006; accepted February 7, 2007.

Address correspondence to: Dr. Subhash C. Gautam, Surgical Research 4D, One Ford Place, Detroit, MI 48202. E-mail: sgautam1{at}hfhs.org




This article has been cited by other articles:


Home page
BloodHome page
Y. Jiao, J. Wilkinson IV, X. Di, W. Wang, H. Hatcher, N. D. Kock, R. D'Agostino Jr, M. A. Knovich, F. M. Torti, and S. V. Torti
Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator
Blood, January 8, 2009; 113(2): 462 - 469.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Yu, G. Shen, T. O. Khor, J.-H. Kim, and A.-N. T. Kong
Curcumin inhibits Akt/mammalian target of rapamycin signaling through protein phosphatase-dependent mechanism
Mol. Cancer Ther., September 1, 2008; 7(9): 2609 - 2620.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.